ARMO BioSciences Decloaks With $20 Million Cash, Focus On Cancer
11/25/2013 9:01:58 AM
ARMO BioSciences Inc. is emerging from stealth mode with powerful science, leaders and funders. The Redwood City company, launched by a trio of former employees at the legendary DNAX Research Institute in Palo Alto, is playing off the boom in cancer immunotherapy research and drugs. But its focus on an extended-play version of the cell-signaling protein interleukin-10, or IL-10, could quickly expand as well into fibrotic diseases, such as the lung-scarring idiopathic pulmonary fibrosis, high cholesterol and inflammatory diseases.
Help employers find you! Check out all the jobs and post your resume.